|                                    | Item<br>No | Recommendation   |          |   |
|------------------------------------|------------|--|----------|---|
| Title and abstract                 | 1          | (a) Indicate the study's design with a commonly used term in the title or the abstract   | ✓        | Page 3 line 14-23                                 |
|                                    |            | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | ✓        | Page 3 line 2-<br>Page 4 line 13                  |
| T . 1                              |            | what was done and what was found   |          | rage 4 line 13                                    |
| Introduction  Background/rationale | 2          | Explain the scientific background and rationale for the investigation being reported   | <b>✓</b> | Page 5 line 22-<br>Page 6 line 2                  |
| Objectives                         | 3          | State specific objectives, including any prespecified hypotheses   | <b>✓</b> | Page 6 line 2-6                                   |
|                                    |            | State specific objectives, including any prespective hypotheses  |          | rage o line 2-0                                   |
| Methods Study design               | 4          | Present key elements of study design early in the paper  | ✓        | Page 6 line 9-<br>Page 7 line 2                   |
| Setting                            | 5          | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | ✓        | Page 6 line 9-20                                  |
| Participants                       | 6          | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  Case-control study—For matched studies, give matching criteria and | √<br>N/A | Page 6 line 9-20                                  |
| Variables                          | 7          | the number of controls per case  Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  | ✓        | Page 7 line 4-<br>Page 8 line 13                  |
| Data sources/<br>measurement       | 8*         | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group   | ✓        | Page 8 line 7-13                                  |
| Bias                               | 9          | Describe any efforts to address potential sources of bias  | ✓        | Page 6 line 13-19 Page 16 line 19- Page 17 line 6 |
| Study size                         | 10         | Explain how the study size was arrived at  | ✓        | Page 6 line 9-20                                  |
| Quantitative variables             | 11         | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | ✓        | Page 8 line 7-13                                  |
| Statistical methods                | 12         | (a) Describe all statistical methods, including those used to control for confounding  | ✓        | Page 8 line 15-27                                 |
|                                    |            | (b) Describe any methods used to examine subgroups and interactions  | ✓        | Page 8 line 15-21                                 |
|                                    |            | (c) Explain how missing data were addressed  | ✓        | Page 8 line 15-27                                 |
|                                    |            | (d) Cohort study—If applicable, explain how loss to follow-up was addressed  Case-control study—If applicable, explain how matching of cases and controls was addressed  Cross-sectional study—If applicable, describe analytical methods  | 1        | Page 8 line 15-27                                 |

taking account of sampling strategy / Page 8 line 15-27 (e) Describe any sensitivity analyses **Results Participants** 13\* (a) Report numbers of individuals at each stage of study—eg numbers 1 Page 9 line 1-7 potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage / Page 9 line 2-7 Page 6 line 9-20 (c) Consider use of a flow diagram N/A Descriptive data 14\* (a) Give characteristics of study participants (eg demographic, clinical, 1 Page 9 line 2-7 social) and information on exposures and potential confounders / Page 9 line 2-7 (b) Indicate number of participants with missing data for each variable Page 6 line 17-18 of interest (c) Cohort study—Summarise follow-up time (eg, average and total N/A 15\* Outcome data Cohort study—Report numbers of outcome events or summary N/A measures over time Case-control study—Report numbers in each exposure category, or N/A summary measures of exposure Cross-sectional study—Report numbers of outcome events or / Page 6 line 1-14 summary measures Main results (a) Give unadjusted estimates and, if applicable, confounder-adjusted / Page 10 line 11-16 estimates and their precision (eg, 95% confidence interval). Make Page 11 line 2, clear which confounders were adjusted for and why they were Page 11 line 13included 26 Page 10 line 11-(b) Report category boundaries when continuous variables were categorized Page 11 line 2, Page 11 line 13-26 Page 10 line 11-(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Page 11 line 2, Page 11 line 13-26 Report other analyses done—eg analyses of subgroups and Page 9 line 16-17 Other analyses interactions, and sensitivity analyses Page 10 line 9, Page 11 line 4-11, Page 11 line 28-Page 12 line 6.

| line 9-17 |
|-----------|
|           |
| line 19-  |
| line 9    |
|           |
| line 29-  |
| line 6    |
|           |
| line 2-4  |
|           |

## Other information

**Funding** Give the source of funding and the role of the funders for the present

study and, if applicable, for the original study on which the present

Page 23 line 11-

12

article is based

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.